The Patent Finder

Aligos Therapeutics, Inc.

34 patents currently held · Updated Nov 18, 2026
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2039
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Mar 19, 2027
  • 3 fees due Apr 17 to 24, 2027 · next Apr 17
  • 1 fee due May 21, 2027
    The maintenance fee for Tricyclic Compounds (US 11,820,773) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
  • 2 fees due Jun 12 to 19, 2027 · next Jun 12
  • 1 fee due Jul 2, 2027
    The maintenance fee for Bicyclic Pyridazinones and Methods of Use Thereof (US 11,858,913) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 1 fee due Sep 26, 2027
    The maintenance fee for Methods and compositions for targeting PD-L1 (US 11,939,581) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
  • 2 fees due Oct 9 to 16, 2027 · next Oct 9

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 11,166,976S-antigen transport inhibiting oligonucleotide polymers and methods
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,033,556Bicyclic sulfonamides
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,198,699Compounds targeting PRMT5
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,091,467Modulators of Thr-Beta and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,180,192Modulators of Thr-Beta and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,599,582Pyrrole Compounds
In force
 · High confidence
In forceHigh confidence
US 11,136,321Tricyclic compounds
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,466,274Modified gapmer oligonucleotides and methods of use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,464,783Heterocyclic compounds
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,613,750Methods of Reducing Virus Molecule Levels
In force
 · High confidence
In forceHigh confidence
10 of 34 patents shown.
Pro members see all 34.
Pro members: see all 34 patents
Also on record, not counted in the 34: 6 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

12 pending · 2 abandoned · 12 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited